RESEARCH TRIANGLE PARK, NC – July 10, 2012 – Quintiles today introduced Allume™, a comprehensive go-to-market service to help biopharmaceutical companies efficiently launch new products and shorten timelines to peak sales, while retaining strategic and corporate control of their assets. Allume™ simplifies and organizes the complex and resource-intensive launch planning process; provides unique data-driven insights from 15 years of market entry experience across the globe; and taps Quintiles’ local market and therapeutic category expertise.
“Biopharma companies are looking for new ways to optimize product value, expedite market access, mitigate commercialization risk, yet retain asset value, while reaching patients across diverse geographic regions,” said Dean Summerfield, Vice President, Consulting, Quintiles. “To maximize value, they need to start planning product launch early in the drug development process, especially when preparing to enter new geographic markets. Through Allume™ Quintiles provides the strategic thinking, local market knowledge, deep therapeutic insight and market access approaches to help our customers map and navigate a pathway to commercial success.”
A unique combination of Consulting, Clinical and Commercial expertise, paired with state-of-the-art software, Allume™ incorporates Quintiles’ years of biopharma product launch experience into flexible, seamless support that complements in-house capabilities. It can be fully customized to each company and product to help identify key market challenges, fast-track launch rollout and improve efficiency in resource management. This cost-effective solution allows companies to benefit from Quintiles’ product lifecycle expertise rather than assume the financial risk of creating their own infrastructure to support launch planning early in the commercialization process.
“Allume™ coordinates decision making around the late phases of development as well as the launch of an asset,” said Dr. Michael Ackermann, Senior Vice President, Global Commercial Solutions at Quintiles. “It is a well-structured and interactive way of accessing the expertise customers need without surrendering strategic control of their asset.”
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
2 Commerce Drive
Cranbury, NJ 08512